Gyre Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Gyre Therapeutics, Inc. (GYRE) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 40.23 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-07
- Gyre Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 40.23M shares, a 25.76% increase year-over-year.
- Gyre Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 17.12M shares, a 1382.31% increase year-over-year.
- Gyre Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 257.46K shares, a 72.10% decline year-over-year.
- Gyre Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 31.99M shares, a 13004.65% increase year-over-year.
- Gyre Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 439.46K shares, a 51.01% decline from fiscal 2024.
- Gyre Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 896.96K shares, a 96.75% decline from fiscal 2023.
- Gyre Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 27.59M shares, a 79.11% decline from fiscal 2022.
- Gyre Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 132.08M shares, a 4972.70% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 40.23M shares 10-Q · filed 2026-08-07 | 40.23M shares 10-Q · filed 2026-08-07 | |||||
| 2026-03-31 | 17.12M shares 10-Q · filed 2026-05-08 | ||||||
| 2025-12-31 | 439.46K shares 10-K · filed 2026-03-13 | ||||||
| 2025-09-30 | 257.46K shares 10-Q · filed 2025-11-07 | 439.46K shares 10-Q · filed 2025-11-07 | |||||
| 2025-06-30 | 31.99M shares 10-Q · filed 2026-08-07 | 137.46K shares 10-Q · filed 2025-08-11 | 32.05M shares 10-Q · filed 2026-08-07 | 137.46K shares 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | 1.15M shares 10-Q · filed 2026-05-08 | ||||||
| 2024-12-31 | 896.96K shares 10-K · filed 2026-03-13 | ||||||
| 2024-09-30 | 922.96K shares 10-Q · filed 2025-11-07 | 870.39K shares 10-Q · filed 2025-11-07 | |||||
| 2024-06-30 | 244.09K shares 10-Q · filed 2025-08-11 | 191.52K shares 10-Q · filed 2025-08-11 | |||||
| 2024-03-31 | 128.03K shares 10-Q · filed 2025-05-09 | ||||||
| 2023-12-31 | 27.59M shares 10-K · filed 2025-03-17 | ||||||
| 2023-09-30 | 131.65M shares 10-Q · filed 2023-10-26 | ||||||
| 2023-06-30 | 8.25M shares 10-Q · filed 2023-08-14 | ||||||
| 2023-03-31 | 8.25M shares 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | 132.08M shares 10-K · filed 2023-03-30 | ||||||
| 2022-09-30 | 7.03M shares 10-Q · filed 2023-10-26 | ||||||
| 2022-06-30 | 2.51M shares 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | 2.78M shares 10-Q · filed 2023-05-15 | ||||||
| 2021-12-31 | 2.60M shares 10-K · filed 2023-03-30 | ||||||
| 2021-09-30 | 3.02M shares 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | 3.24M shares 10-Q · filed 2022-08-15 | ||||||
| 2021-03-31 | 3.21M shares 10-Q · filed 2022-05-09 | ||||||
| 2020-12-31 | 2.36M shares 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | 2.26M shares 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | 2.01M shares 10-Q · filed 2021-08-05 | ||||||
| 2020-03-31 | 1.98M shares 10-Q · filed 2021-05-06 | ||||||
| 2019-12-31 | 1.59M shares 10-K · filed 2021-03-04 | ||||||
| 2019-09-30 | 1.58M shares 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | 1.66M shares 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | 1.62M shares 10-Q · filed 2020-05-11 | ||||||
| 2018-12-31 | 1.37M shares 10-K · filed 2020-02-20 | ||||||
| 2018-09-30 | 1.33M shares 10-Q · filed 2019-11-07 | ||||||
| 2018-06-30 | 1.08M shares 10-Q · filed 2019-08-01 | ||||||
| 2018-03-31 | 1.04M shares 10-Q · filed 2019-05-02 | ||||||
| 2017-12-31 | 3.35M shares 10-K · filed 2019-03-08 | ||||||
| 2017-09-30 | 3.96M shares 10-Q · filed 2018-11-01 | ||||||
| 2017-06-30 | 3.31M shares 10-Q · filed 2018-08-02 | ||||||
| 2017-03-31 | 230.00K shares 10-Q · filed 2018-05-03 | ||||||
| 2016-12-31 | 293.80K shares 10-K · filed 2018-03-19 | ||||||
| 2016-09-30 | 5.60M shares 10-Q · filed 2016-11-03 | ||||||
| 2016-06-30 | 5.80M shares 10-Q · filed 2016-08-04 | ||||||
| 2016-03-31 | 5.76M shares 10-Q · filed 2016-05-05 | ||||||
| 2015-12-31 | 403.57K shares 10-K · filed 2017-03-08 | 6.05M shares 10-K · filed 2016-03-09 | |||||
| 2015-09-30 | 5.57M shares 10-Q · filed 2015-11-05 | ||||||
| 2015-06-30 | 3.05M shares 10-Q · filed 2015-07-31 | 99.91M shares 8-K/A · filed 2015-10-23 | 3.42M shares 10-Q · filed 2015-07-31 | ||||
| 2015-03-31 | 3.80M shares 10-Q · filed 2015-05-07 | ||||||
| 2014-12-31 | 3.63M shares 10-K · filed 2016-03-09 | 4.68M shares 10-K · filed 2015-03-16 | |||||
| 2014-09-30 | 4.69M shares 10-Q · filed 2014-11-06 | 4.81M shares 10-Q · filed 2014-11-06 | |||||
| 2014-06-30 | 4.79M shares 10-Q · filed 2015-07-31 | 4.87M shares 10-Q · filed 2015-07-31 | |||||
| 2014-03-31 | 4.95M shares 10-Q · filed 2015-05-07 | ||||||
| 2013-12-31 | 3.45M shares 10-K · filed 2016-03-09 | 4.36M shares 10-K · filed 2014-03-14 | |||||
| 2013-09-30 | 4.81M shares 10-Q · filed 2014-11-06 | 4.77M shares 10-Q · filed 2014-11-06 | |||||
| 2013-06-30 | 4.71M shares 10-Q · filed 2014-08-07 | 4.74M shares 10-Q · filed 2014-08-07 | |||||
| 2013-03-31 | 4.78M shares 10-Q · filed 2014-05-08 | ||||||
| 2012-12-31 | 4.25M shares 10-K · filed 2015-03-16 | ||||||
| 2012-09-30 | 4.54M shares 10-Q · filed 2013-11-06 | 3.65M shares 10-Q · filed 2013-11-06 | |||||
| 2012-06-30 | 3.79M shares 10-Q · filed 2013-08-07 | 3.28M shares 10-Q · filed 2013-08-07 | |||||
| 2012-03-31 | 2.47M shares 10-Q · filed 2013-05-08 | ||||||
| 2011-12-31 | 3.60M shares 10-K · filed 2014-03-14 | ||||||
| 2011-09-30 | 3.80M shares 10-Q · filed 2012-11-08 | 1.58M shares 10-Q · filed 2012-11-08 | |||||
| 2011-06-30 | 3.80M shares 10-Q · filed 2012-08-09 | 1.41M shares 10-Q · filed 2012-08-09 | |||||
| 2010-12-31 | 850.68K shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |